Startup Vitalunga creates novel oral drug to enable disease-free aging; pre-clinical studies expected to begin in near future

/PRNewswire/ -- Vitalunga, the biotech startup based on the research led by Professor Einav Gross and Professor Shmuel Ben-Sasson of The Hebrew University's...

Related Keywords

Boston ,Massachusetts ,United States ,Jerusalem ,Israel General ,Israel ,Japan ,Hebrew University ,Yerushalayim ,Shmuel Ben Sasson ,Einav Gross ,Prnewswire Vitalunga ,Muli Ben Sasson ,Itzik Goldwaser ,Hebrew University Portfolio Company ,Hebrew University Faculty Of Medicine ,Boston Scientific ,Novartis ,Hebrew University Of Jerusalem ,Johnson ,Intel ,Professor Einav Gross ,Professor Shmuel Ben Sasson ,Professor Ben Sasson ,Population Aging ,Professor Muli ,Professor Gross ,